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                                          INTRODUCTION 
The pharmaceutical industry is a vital segment of the health care system that conducts research, 
manufactures and markets pharmaceuticals and biological products for the treatment and diagnosis 
of diseases. 
The increasing path way of research in pharmaceutical industries has resulted in emergence of 
novel and competent formulations in market. Some of this dosage forms are highly potent whereas 
some contain impurities. Such development naturally requires precise, easy and sensitive methods 
of chemical analysis, as quality is very important in a pharmaceutical product. Since it involves 
life, unlike other customer goods there can be and there is no second quality in medicines. Quality 
can be also achieved through the quality control department and quality assurance. 
Quality control: 
Quality control department is responsible for day-to-day control of quality within a company. The 
department does the analytical testing of the raw materials, intermediates and finished products as 
well as the inspection of the packaging components. 
Quality assurance: 
Quality assurance is defined as the activity of providing to all concerned; the evidence needed to 
establish confidence that the quality function is being performed adequately. It covers all matter, 
which individually or collectively influence the quality of a product. It ensures that quality is built 
in to the product, beginning with research and development, through testing and production of the 
final product. 
Stability is a chief quality characteristic of the pharmaceutical products and any deviation from the 
pre-set limits may affect the safety and efficacy of the products and thereby may found unsuitable 
for the intended purpose. Establishing the stability profile of pharmaceutical product is the key 
chemistry, manufacturing and controls development activity which includes a number of pre –
determined scientific studies on the active entity, intermediates and the finished product under 
various conditions. It is vital to be noted that all the possible environment conditions under the 
product could be exposed, starting from manufacturing throughout the supply chain. 
Stability testing is the primary tool used to assess the expiry determination and storage conditions 
for a particular pharmaceutical product. Stability testing includes long-term studies, where the 
product is usually stored at room temperature and humidity conditions. Where as in the case of 
acceleration studies the product is stored under the conditions of high temperature and humidity. 
Optimum design, practical implementation, monitoring and assessment of the studies are also 
important for obtaining required and precise stability data. 
The container closure system also should be scrutinized for its compatibility with the drug 
substance and its formulation to make sure that the container does not give a chance to degrade or 
deteriorate. 
The stability study usually consists of a serious of tests performed in order to obtain an assurance 
of the stability of a drug product, namely maintenance of the specifications of the drug product 
packed in its specified packaging material and stored in the established storage condition within 
the determined time period. 
1.1  Different types of pharmaceutical dosage forms. 
1. Solid dosage forms: 
a) Tablets 
b) Capsules 
c) Pills 
 
2. Liquid dosage forms: 
a) Sterile products: Eye drops, injections etc. 
b) Non-sterile products: Syrups, solutions etc. 
 
3. Semi-solid dosage forms: 
a) Ointments 
b) Creams 
The stability studies of these dosage forms have to be performed in their respective container 
closure system to concentrate the integrity of the product throughout its self-life. 
Stability studies are an integral part of the drug development program. Stability assessment begins 
with studies on the drug substances to determine degradation products and mechanism of 
breakdown, the conditions under which this breakdown occurs, and appropriate methodology for 
assessing stability. This is followed by long-time stability studies on development lots, storage at 
normal and accelerated conditions in the proposed container intended for storage and shipping and 
studies on large scale lots. Stability studies on the drug product are designed using the information 
gained on the drug substance. 
These normally begin with the compatibility study on the drug when mixed with its excipients 
corresponding to the formulation and thereby consecutively to eliminate any excipients which 
tends to cause a loss in potency of the chief chemical substance during its storage. Stability studies 
are normally performed on development lots before the intended formulations for marketing is 
finalized. Studies are then migrated on to large scale batches, which is a representation of the 
commercial product. The final stage of the stability study is the framing of a protocol intended for 
the future stability studies. 
The purpose of stability testing is to provide evidence on how the quality of an active substance or 
pharmaceutical product varies with time under the influence of a variety of environmental factors 
such as temperature, humidity and light. In addition, product-related factors influence the stability, 
e.g. the chemical and physical properties of the active substance and the pharmaceutical 
excipients, the manufacturing process, dosage forms and its composition, the nature of the 
container-closure system and the properties of the packaging materials. Also, the stability of 
excipients that may contain or form reactive degradation products, have to be considered. As a 
result of stability testing a re-test period for the active substance or a shelf life for the 
pharmaceutical product can be established, and storage conditions can be recommended. 
GUIDELINES FOR STABILITY STUDIES 
Guidelines are nothing but a set of pre-set rules and laws to comply with a particular procedure to 
ensure that the predetermined guideline fetches the intended results. 
When it comes to the area of stability study there are various guidelines which are set by various 
countries, committees and regulatory bodies. Out of which few are listed below, 
1) ICH Guideline 
2) USFDA guideline 
3) WHO  guideline 
 
ICH Guideline: 
Stability testing of Drug substances and product. 
1. INTRODUCTION 
 
1.1 Objectives of the guideline 
 The following guideline is a revised version of the ICHQ1A guideline and defines the stability 
data package for a new drug substance or a product that is sufficient for a registration within in 
three religions of the Europe, Japan and the United States. 
The guideline seeks to exemplify the core stability data package for new substances and products 
but leaves sufficient flexibility to encompass the variety of different practical situations that may 
be encountered due to specific scientific considerations and characteristics of the materials being 
evaluated. 
1.2 Scope of the guideline 
The guideline addresses the information to be submitted in the registration application for new 
molecular entities and associated drug products. 
1.3 General principles 
The purpose of stability testing is to provide evidence how the quality of the drug or drug product 
varies with time under the influence of environmental factors such as temperature, humidity and 
light.  
To establish a retest period for the drug substance or a shelf life for the drug product and 
recommend storage conditions. 
The choice of test conditions defined in this guideline is based on the analysis of effects of 
climatic conditions in the three regions of the EC, Japan and the United States. The mean kinetic 
Temperature in any part of the world can be derived from the climatic data and the world can be 
divided in to four climatic zones, 1-4. This guideline addresses the climatic zones 1&2. 
 
2. GUIDELINES  
2.1 Drug substance 
 
 
2.1.1 General 
Information on the stability of the drug substance is an integral part of the system approach to the 
stability evaluation. 
2.1.2 Stress testing 
Stress testing of the drug can help identify the likely degradation products, which can in turn help 
establish the degradation pathways and the intrinsic stability of the molecule and validate the 
stability indicating power of the analytical procedure used. 
Stress testing is likely to be carried out on a single batch of the drug substance. it should include 
the effect of temperature (in 10ºc increments) above that for accelerated testing, humidity (eg75% 
RH) where appropriate oxidation ,and photolysis on the drug substances. The testing should also 
evaluate the susceptibility of the drug substance to hydrolysis across a wide range of pH values 
when in the solution or suspension. 
2.1.3 Selection of batches 
Data form the formal stability studies should be provided on a least three primary batches of the 
substance. The batches should be manufactured to a minimum pilot scale by the same synthetic 
route as and using a method of manufacture and procedure that stimulates the final process to be 
used for production batches. The overall quality of the batches of drug substance placed on formal 
stability studies should be representative of the quality of the material to be made on a production 
scale. 
2.1.4 Container closure system 
The stability studies should be conducted on the drug substance packaged in a container closure 
system that is the same as or stimulates the packaging proposed for storage and distribution. 
2.1.5 Specification 
 Specification, which is a list of tests, reference to the analytical procedures, and proposed 
acceptance criteria, is addressed in ICHQ6A and Q6B. In addition, specification for degradation 
products in a drug substance is discussed in Q3A.Stability studies should include testing those 
attributes of the drug substance that are susceptible to change during storage and are likely to 
influence quality, safety and or efficacy. The testing should cover an appropriate, the physical, and  
chemical, biological and microbiological attributes. Validated stability - indicating analytical 
procedures should be applied whether and to what extend replication should be performed will 
depend on the results from validation studies. 
2.1.6 Testing frequency: 
 For long term studies, frequency of testing should be sufficient to establish the stability profile of 
the drug. For drug substance with a proposed re test period of at least 12 months, the frequency of 
testing at the long term storage should normally be every 3 months over the first year, every 6 
months over the second year ,and annually thereafter through the proposed re test period. 
At the accelerated storage condition, a minimum of three time points, including the initial and 
final time points(eg:0, 3 and 6 months) from a 6 months study is recommended. Where an 
expectation (based on development experience) exists that results from accelerated studies are 
likely to approach significant change criteria, increased testing should conducted either by adding 
samples at the final time point by including a fourth time point in the study design. 
 When testing at the intermediate storage condition is called for as result of significant change at 
the accelerated storage condition, a minimum of four points, including the final and initial points 
(0, 6, 9, 12) from a 12 month study is recommended. 
2.1.7 Storage conditions: 
In general a drug substance should be evaluated under storage conditions (with appropriate 
tolerances) that test its thermal stability and if applicable its sensitivity to moisture. The long term 
testing should cover a minimum of 12 months duration on at least three primary batches at the 
time of submission and should be continued for a period of time sufficient to cover the proposed 
re-test period. Additional data accumulated during the assessment period of the registration 
application should be submitted to the authorities if requested. Data from the accelerated storage 
condition can be used to evaluate the effect of short term excursions outside the label storage 
conditions (such as might occur during shipping). 
Long term, accelerated, and where appropriate, intermediate storage conditions for the drug 
substances are detailed in the section below. The general case applies if the drug substances are 
not specifically covered by subsequent section .alternative storage conditions can be used if 
justified 
 
General Considerations 
Summary of Stability Parameters  
Table No: 1 
Study Storage Condition Minimum 
Time Period 
Comments 
General Case : 
Long-term 
25 ºC ± 2 ºC/ 60% RH ± 5% 
RH or 30 ºC ± 2 ºC/ 65% RH 
± 5% RH 
12 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
General Case : 
Intermediate 
30 ºC ± 2 ºC/ 65% RH ± 5% 
RH 
6 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
General Case : 
Accelerated 
40 ºC ± 2 ºC/ 75% RH ± 5% 
RH 
6 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
Refrigeration : 
Long-term 
5 ºC ± 3 ºC 12 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
Refrigeration : 
Accelerated 
25 ºC ± 2 ºC/ 60% RH ± 5% 
RH 
6 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
Freezer : 
Long-term 
-20 ºC ± 5 ºC 12 months Must cover retest or shelf life 
period at a minimum and 
includes storage, shipment and 
subsequent use. 
 
If long term studies are conducted at 25◦c±2ºc RH±5% and “significant change “ occur at any time 
during 6 months, testing at the accelerated storage condition, additional testing at the intermediate 
storage condition should be conducted and evaluation against significant change criteria 
Testing at the intermediate storage condition should include all tests, unless otherwise justified the 
initial application should include a minimum of 6 months data from a 12 month study at the 
intermediate storage condition. 
Data from refrigerated storage should be assessed according to the evaluation section of this 
guideline, expect where explicitly noted below. 
If significant change occurs between 3 and 6 months, testing at the accelerated storage condition 
the proposed re test period should be based on the real time data available at the long term storage 
condition. 
2.1.8 Stability Commitment 
When available long term stability data on primary batches do not cover  the proposed re-test 
period granted at the time of approval , a commitment should be made to continue the stability 
studies post approval in order to firmly established the re test period. 
Where the submission includes long term stability data on three production batches covering the 
proposal re-test period, a post approval commitment is considered unnecessary. Otherwise one of 
the following commitments should be made: 
1. If the submission includes data from the stability studies of at least three production 
batches, a commitment should be made to continue these studies through the proposed re-
test period. 
2. If  the submission includes data from the stability studies on fewer than three production 
batches, a commitment should be made to continue these studies through the proposed re-
test period and to place additional production batches, to a total of at least three, on long 
term stability studies through the proposed re-test period. 
3. If the submission does not include stability data on production batches, a commitment 
should be made to place the first three production batches on long term stability  studies 
through the proposed re test period. 
 
The stability protocol used for the long-term studies for the stability commitment should be the 
same as that for the primary batches, unless otherwise scientifically justified. 
2.1.9 Evaluation 
The purpose of the stability study is to establish ,based on testing a minimum of three batches of 
the drug substance and  evaluating the stability information(including as appropriate to all the 
physical, chemical, biological and microbiological tests) a re-test period applicable to all future 
batches of the drug substance manufactured under similar circumstances. The degree of variability 
of individual batches affects the confidence that a future production batch remain within 
specification throughout the assigned re-test period. 
The data may show so little degradation and so little variability that it is apparent from looking at 
the data that the requested re-test period will be granted. Under these circumstances, it is normally 
unnecessary to go through the formal statistical analysis, providing a justification for the omission 
should be sufficient. 
An approach for analysing the data on a quantitative attribute that is expected to change with time 
is to determine the time at which the 95% one sided confidence limit for the mean curve intersects 
the acceptance criterion. If analysis shows the batch to batch variability is small, it is advantageous 
to combine the data into one overall estimate. This can be done by first applying appropriate 
statistical test (e.g. p values for level of significance of rejection of more than 0.25) 
To the slopes of the regression lines and zero time intercepts for the individual batches. If it is 
inappropriate to combine data from several batches, the over-all retest period should be based on 
the minimum time a batch can be expected to remain within acceptance criteria. 
The nature of any degradation relationship will determine whether the data should be transformed 
of linear regression analysis. usually the relationship can be represented by a linear, quadratic or 
cubic function on an arithmetic or logarithmic scale .statistical methods should be employed to test 
the goodness of fit of the data on all batches and combined batches(where appropriate) to the 
assumed degradation line or curve. 
Limited extrapolation of the real time data from the long term storage condition beyond the 
observed range to extend the re-test period can be undertaken at approval time, if justified. This 
justification should be based on what is known about the mechanism of degradation, the results of 
testing under accelerated conditions, the goodness of fit of any mathematical model, batch size, 
existence of supporting stability data etc.  
However, this extrapolation assumes that the same degradation relationship will continue to apply 
beyond the observed data. Any evaluation should cover not only the assay, but also the levels of 
degradation products and other appropriate attributes. 
2.1.10 Statements / Labelling 
A storage statement should be established for the labelling in accordance with relevant 
national/regional requirements. The statement should be based on the stability evaluation of the 
drug substance. Where applicable, specific instruction should be provided,  particularly for drug 
substances that cannot tolerate freezing. Terms such as “ambient conditions” or “room 
temperature” should be avoided. 
There should be a direct link between the label storage statement and the demonstrated stability of 
the drug product. An expiration date should be displayed on the container.  
A re- test period should be derived from the stability evaluation and a retest date should be 
displayed on the container label if appropriate 
 
Scheme of protocol for stability study of adapalene 
1. Scope:  
Scale up batch 
 
2. Purpose:  
New product 
 
3. Reference: 
 SOP on general stability programme 
 
4. Market:  
Global 
 
 
 
5. Ingredient details: 
Table No: 2  
Ingredients Label claim Input 
 
Adapelene 
 
 
Preservatives: 
Methylparaben 
Phenoxyethanol 
Each g gel contains 
1 mg of adapelene 
 
Each g gel contains: 
1 mg of Methylparaben 
2.5 mg of Phenoxyethanol 
 
1 mg of adapelene 
 
 
1 mg of Methylparaben 
2.5 mg of Phenoxyethanol 
 
6. API Details: 
Table No: 3 
Ingredients Source AR No: 
Adapelene 
(micronized) 
Zhejiang Neo-Dankong Pharma Ltd 500154616789 
 
7. Primary Packing Details: 
 
Material Specification / Description Manufacturer 
Tubes Laminated tubes Essel pro-pack 
 
 
 
8. Conditions: 
Table No: 4 
 
Condition Table No 
5 ºC ± 3 ºC (refrigerator) A 
40 ºC ± 2 ºC / 75% ± 5% RH (accelerated) B 
30 ºC ± 2 ºC / 65% ± 5% RH (intermediate) C 
25 ºC ± 2 ºC / 65% ± 5% RH (intermediate) D 
30 ºC ± 2 ºC / 60% ± 5% RH (long tem) E 
Others, specify if any NA 
 
9. Number of Samples Required For Testing: 
Table No: 5 
Sl No: Test Parameters No. of units used / test 
1 Description 2 
2 Identification 2 
3 Assay and RS 2 
4 Preservative Content 2 
5 pH 2 
6 Water content 2 
7 In-vitro release 2 
8 Homogeneity 2 
9 Viscosity 1 
10 Microbial Limit Test 1 
 
 
 
Sampling Plan 
Storage Conditions: 
Storage: 40 ºC ± 2 ºC / 75 ± 5% RH 
Table No: 6 
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Initial Y Y Y Y Y Y Y Y Y 7 
1 month Y Y N Y Y Y Y Y Y 7 
2 month Y Y N Y Y Y Y Y Y 7 
3 month Y Y N Y Y Y Y Y Y 8 
6 month Y Y N Y Y Y Y Y Y 8 
Y: Indicates sample to be analysed 
N: Indicates sample to be analysed 
Storage Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Table No: 7  
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Storage Condition: 30 ºC ± 2 ºC / 75% RH ± 5% RH 
Table No: 8 
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3 month Y Y N Y Y Y Y Y Y 6 
6 month Y Y N Y Y Y Y Y Y 7 
9 month     NA      
12 month Y Y N Y Y Y Y Y Y 7 
Drug shelf lives and its parameters-  
Table No: 9  
category             Measurement  Parameters 
 
 
 
 chemical  Remaining percentage  of labelled strength of active drug 
 
 Content of specified degradation products. 
 
  Solution pH 
 
 
Physical   Drug dissolution rate of solid oral dosage forms 
 
 Fully intact integrity of dosage forms. 
 
 Particle size and homogeneity in emulsions, suspensions, and suppositories. 
 
 
 Aesthetic   Colour, odour and texture of drug product 
 
Colour and clarity of label 
 
 
 
 
Terms and Definitions used under stability studies: 
Climatic zones 
The four zones in the world are distinguished by their characteristic prevalent annual climatic 
conditions. This is based on the concept described by Grimm.w (Drugs Made in Germany, 28 
:196-202,1985 and 29:39-47,1986) 
Commitment batches 
Production batches of a drug substance or drug product for which the stability studies are initiated 
or completed post approval through a commitment made in the registration application. 
Container closure system 
The sum of packaging components together contains and protects the dosage form. This includes 
primary packaging components and secondary packaging components, if the latter are intended to 
provide additional protection to the drug product. A packaging system is equivalent to a container 
closure system. 
Dosage form 
A pharmaceutical product type (e.g., tablet, capsule, solution, cream)that contains a drug 
substance generally, but not necessarily, in association with excipients. 
Drug product 
The dosage form in the final immediate packaging intended for marketing. 
Drug substance  
The unformulated drug substance that may subsequently be formulated with excipients to produce 
the dosage form. 
Excipient 
Anything other than the drug in the dosage form. 
 
Expiration date 
The date placed on the container label of a drug product designating the time prior to which a 
batch of the product is expected to remain within the approved shelf life specification if stored 
under defined conditions and after which it must not be used. 
Formal stability studies 
Long term and  accelerated (and intermediate) studies undertaken on primary and /or commitment 
batches according  to a prescribed stability protocol to establish or confirm the re-test period of a 
drug substance or the shelf life of a drug product 
Impermeable containers: 
Containers that provide a permanent barrier to the passage of gases or solvents, e.g sealed 
aluminium tubes for semisolids, sealed glass ampoules for solutions. 
Mean kinetic temperature: 
A single derived temperature that, if maintained over a defined period of time, affords the same 
thermal challenge to a drug substance or drug product as would be experienced over a range of 
both higher and lower temperatures for an equivalent defined period. The mean kinetic 
temperature is higher than the arithmetic mean temperature and takes into the account the 
Arrhenius equation.  
When establishing the mean kinetic temperature for a defined period, the formula of Haynes J.D 
(J.Pharm.Sci.,60:927-929,1971) can be used. 
New molecular entity: 
An active pharmaceutical substance not previously contained in any drug product registered with 
the national or regional authority concerned, a new salt, ester, or non-covalent-bond derivative of 
an approved drug substance is considered a new molecular entity for the purpose of stability 
testing under this guidance. 
 
 
 
Pilot scale batch: 
A batch of a drug substance or drug product manufactured by a procedure fully representative of 
and simulating that is to be applied to a full production scale batch. For solid oral dosage forms a 
pilot scale is generally, at a minimum, one-tenth that of a full production scale or 100,000 tablets 
or capsules, wherever is the larger. 
Primary batch: 
A batch of a drug substance or drug product used in a formal stability study, from which stability 
data are submitted in a registration application for the purpose of establishing a re-test period or 
shelf life, respectively. A primary batch of a drug substance should be at least a pilot scale batch. 
For a drug product, two of the three batches should be at least a pilot scale batch and the batch can 
be smaller if it is representative with regard to the critical manufacturing steps, however, a primary 
batch may be a production batch. 
Production batch: 
A batch of a drug substance or drug product manufactured at production scale by using production 
equipment in a production facility as specified in the application. 
Re-test date: the date after which samples of the drug substance should be examined to ensure 
that the material is still in compliance with the specification and thus suitable for use in the 
manufacture of a given drug product. 
Re-test period: 
The period of time during which the drug substance is expected to remain within its specification 
and therefore, can be used in the manufacture of a given drug product, provided that the drug 
substance has been stored under the defined conditions. After this period, a batch of drug 
substance destined for use in the manufacture of a drug product should be retested for compliance 
with the specification and then used immediately. A batch of drug substance can be retested 
multiple times and a different portion of the batch used after each re –test, as long as it continues 
to comply with the specification. For most biotechnological/biological substances known to be 
labile, it is more appropriate to establish a shelf life than a re-test period. The same may be true for 
certain antibiotics. 
 
Semipermeable membrane: 
Containers that allow the passage of solvent, usually water while preventing solute loss. The 
mechanism for solvent transport occurs by absorption into one container surface, diffusion through 
the bulk of the container material, and desorption from the other surface. Transport is driven by a 
partial pressure gradient. Examples of semipermeable containers include plastic bags and semi-
rigid, low-density polyethylene (LDPE) pouches for large volume parental (LVPs) and LDPE 
ampoules, bottles, and vials. 
Shelf life (also referred to as expiration dating period): 
The time period during which a drug product is expected to remain within the approved shelf life 
specification, provided that it is stored under the conditions defined on the container label. 
Specification: 
Specification is a list of tests, reference to analytical procedures, and proposed acceptance criteria, 
including the concept of different acceptance criteria for release and shelf life specifications. 
Specification- release: 
The combination of physical, chemical, biological and microbiological tests and acceptance 
criteria that determine the suitability of a drug product at the time of  its release. 
Specification – shelf life: 
The combination of physical, chemical, biological, and microbiological tests and acceptance 
criteria that determine the suitability of a drug product throughout its re-test period, or that a drug 
product should meet throughout its shelf life. 
Storage condition tolerances: 
The acceptance variations in temperature and relative humidity of storage facilities are for formal 
stability studies. The equipment should be capable of controlling the storage condition within the 
ranges defined in this guideline. The actual temperature and humidity (when controlled) should be 
monitored during stability storage. Short term spikes due to opening doors of the storage facility 
are accepted as unavoidable. The effect of excursions due to equipment failure should be 
addressed, and reported if judged to effect stability results. Excursions that exceed the defined 
tolerances for more than 24 hours should be described in the study report, and their effect 
assessed. 
Stress testing (drug substance): 
Studies undertaken to elucidate the intrinsic stability of the drug substance is known as stress 
testing of drug substance. Such testing is the part of development strategy and is normally carried 
out under more severe conditions than those used for accelerated testing. 
Stress testing (drug product): 
Studies undertaken to access the effect of severe conditions on the drug product is known as stress 
testing of drug product. Such studies include photo stability testing and specific testing on certain 
products (e.g., metered dose inhalers, creams, emulsions, refrigerated aqueous liquid products) 
Supporting data: 
Data other than those from formal stability studies, which support the analytical procedures, the 
proposed re-tested period or shelf life, and the label storage statements. Such data includes (1) 
stability data on early synthetic route batches of drug substances, small scale batches of materials 
,investigational formulations not proposed for marketing ,related formulations, and product 
presented in containers and closures other than those proposed for marketing (2) information 
regarding test results on containers, and (3)other scientific rationales. 
INTERNATIONAL CLIMATIC ZONES     Table No: 10 
       ZONES AVERAGE 
ANNUAL 
TEMPERATURE 
MKT(mean kinetic 
temperature) 
 Average humidity 
 Temperature 
United Kingdom, 
Northern Europe, 
Canada ,Russia 
 
 20⁰C 
 
     21⁰C 
 
     45% 
Mediterranean 
United States, Japan, 
Southern Europe 
(Portugal Greece) 
 
       20.5 -24⁰C 
 
     26⁰C 
 
     60% 
Hot dry 
Iran, Iraq, Sudan. 
India 
 
 24⁰C 
 
     31⁰C 
 
     40% 
Hot and humid 
Brazil, Ghana, India, 
Indonesia 
 
 24⁰C 
 
     31⁰C 
 
     70% 
 
Chromatographic   methods: 
Chromatography  is a technique  by  which  solutes  of  two  or more components are separated by 
a dynamic  differential  migrational  process, in  a system consist  of  two  phases, one  of which  
moves  continuously  in  a given direction and in which the individual  component  exhibits  
different mobility due  to difference   in  adsorption  or  partition  or molecular size,  ion exchange 
etc. There are various advanced chromatographic techniques which are most reliable and widely 
used for the estimation of the multicomponent drugs in their formulations namely Gas 
chromatography (GC), High performance liquid chromatography (HPLC) and High performance 
thin layer chromatography (HPTLC). 
a) Gas liquid chromatography(GLC): 
In this technique, a carrier gas   is used a mobile phase and it is passes over a stationary phase. It 
employs a liquid non- volatile stationary phase, coated on an inert solid support and separation is 
according to the difference in partition coefficient of components in a mixture. The separation is 
achieved by changes in nature of stationary phase, carrier gas flow, change in column temperature 
etc. The quantification is done by measurement of recorded peak area or peak height which is 
directly proportional to concentration of the analyte. 
. 
b) High performance liquid chromatography (HPLC): 
The technique of HPLC is so called because of its improvement performance in terms of rapidity, 
specificity, sensitivity, accuracy, convenience, ease of automation and the cost of analysis when 
compared to classical column chromatography. Advances in column technology high pressure 
pumping system and sensitive detectors have transformed liquid column chromatography in to a 
high speed, efficient, accurate, and highly resolved method of resolution. 
  c) High performance thin layer chromatography (HPTLC): 
The term HPTLC is used for the technique in which substance are accurately and precisely 
assayed during high performance grade of silica gel. HPTLC is a sophisticated and automated 
form of TLC, which is the modern thin layer chromatographic technique and has the following 
synonyms 
 
 Planar chromatography. 
 Instrumental thin layer chromatography. 
 Planar liquid chromatography. 
 
  
                                                       Fig.1 HPLC instrument 
 
 
 
 
 
 
                             Fig: 2 Flow Diagram of HPLC 
 
 
Modes of separation in HPLC: 
There are different modes of separation in HPLC. They are normal phase mode, reversed phase 
mode, reversed phase ion pair chromatography, ion exchange chromatography, affinity 
chromatography and size exclusion chromatography (gel permeation and gel filtration 
chromatography). 
Normal phase mode 
In normal phase mode, the nature of stationary phase is polar adsorbent and the mobile phase is 
generally a mixture of non-aqueous solvents. The silica structure is saturated with silanol group at 
the end in normal phase separations. These OH groups are statistically distributed over the whole 
of the surface. The silanol groups represent the active sites (very polar) in the stationary phase. 
This forms a weak bond with many molecules in the vicinity when any of the following 
interactions are present. Dipole- induced dipole, dipole-dipole, Hydrogen bonding. These 
situations arise when the molecule has one or several atoms with lone pair electrons or a double 
bond. The adsorption strength and hence „K‟ value (elution series) increase in the following order. 
Saturated hydrocarbons <  olefins < aromatic < organic < halogen compounds < sulphides < 
ethers < esters < aldehydes and ketones < amines < sulphones < amides < carboxylic acids. The 
strength of interactions depends not only on the functional groups in the sample molecule but also 
on stearic factors. If a molecule has several functional groups  in the sample molecule but also on 
stearic factors. If a molecule has several functional groups , then the most polar one determines 
the reaction properties. 
Chemically modified silica, such a aminopropyl, cyanopropyl, and diol phases are the stationary 
phases alternative to silica gel in normal phase chromatography. 
The aminopropyl and cyanopropyl phases provide opportunities for specific interactions between 
the analyte and the stationary phase and thus offer additional options for the optimization of 
separations. Other advantages of bonded phases lie in the increased homogencity of the stationary 
phase surface. 
Polar modifiers such as acetic acid or triethylamine (TEA) are added to the mobile phase, to de 
activate the more polar adsorption sites on the surface of stationary phase, which in turn will 
improve peak shape as well as the reproducibility of the retention times. 
 
 
In this technique, nonpolar compounds travel faster and are eluted first because of the lower 
affinity between the nonpolar compounds and the stationary phase. Polar compounds are retained 
for longer times and take more time to elute because of their higher affinity with the stationary 
phase. Normal phase mode of separation is not generally used for pharmaceutical applications 
because most of the drug molecules are polar in nature and hence take longer time to elute. 
Reverse phase mode 
In 1960s, chromatography started modified the polar nature of the silanol group by chemically 
reacting silicon with organic silanes .The object was to make silica less polar or non polar so that 
polar solvents can be used to separate water soluble polar compounds .Since the ionic nature of 
the chemically modified silica in now reversed .i.e, it is non-polar or the nature of the phase is 
reverted, the chromatographic separation carried out with such silica is referred to as reverse- 
phase chromatography. 
Reverse phase liquid chromatography (RPLC) is considered as the method of choice for the 
analysis of pharmaceutical compounds for many reasons like its compatibility with aqueous and 
organic solutions as well as with different detection systems and its high consistency and 
repeatability. Sensitive and accurate RPLC analysis, whether in the pharmaceutical or bio 
analytical field necessitates the use of stationary phases which give symmetrical and efficient 
peaks. 
Hence manufacturers of stationary phases are continuously improving and introducing new RPLC 
products and the selection of various types of reverse phase stationary phases is high. The needs 
for consistency as well as the globalization of pharmaceutical companies require that the methods 
will be transferred from site to site using either the same column brands or their equivalents. 
Therefore, an extensive categorization or characterization of the rich selection of the stationary 
phases has been done in recent years. 
The stationary phase in the Reverse Phase chromatographic columns is a hydrophobic support that 
mainly consists of porous particles of silica gel in various shapes (spherical or irregular) at various 
diameters(1.8,3,5,7,10 µm etc.) at various pore sizes (such as 60, 100, 120, 300). 
The surface of these particles is covered with various chemical entities, such as various 
hydrocarbons (C1, C6, C4, C8, C18 etc.). In most methods, C18 columns are currently used to 
separate medicinal materials which are sometimes called ODS (octedecylsilane) or RP-18. A polar 
solvent is used as mobile phase. 
 
The parameters that govern the retention in Reverse Phase systems are:- 
1. The chemical nature of the stationary phase  
The chemical nature is determined by the size and chemistry of hydrocarbon bonded on the silica 
gel surface, its bonding density (units of µmole/m²), and the purity and quality of the silica gel 
support. As a rule, the more carbons in a bonded hydrocarbon, the more it retains organic solutes 
(as long as similar % coverage is compared). The higher the bonding density, the longer the 
organic solutes are retained. A column is considered relatively hydrophobic if its bonding density 
exceeds 3 µmole/m². 
Very important modifiers of the stationary phase‟s surface are surface active substances used as 
mobile phase‟s additives, acting as ion pair reagents. These are substances such as tri-ethylamine 
or tetrabutylamine or hexyl, heptyl, octyl sulfonate. They are distributed between the mobile 
phase and the hydrophobic surface and cover it with either positive (alkylamines) or negatives 
(alkyl sulfonates) charges. This change of the surface into charged surface affects the retention 
significantly, especially on charged species in the sample. 
2. Composition of the mobile phase 
As a rule, the weakest solvent in Reverse Phase is the most polar one, water. The other polar 
organic solvents are considered stronger solvents, where the order of solvent strength follows 
more or less their dielectric properties, or polarity. The less polar the solvent added to the mobile 
phase, the stronger it gets, shortening the retention times.  
3. pH and ionic strength of the mobile phase 
When the samples contain solutes of ionisable functional groups such as amines, carboxyls, 
phosphates, phosphonates, sulfates and sulfonates, it is possible to control their ionization degree 
with the help of buffers in the mobile phase. As a rule, the change of an ionisable molecule to an 
ion makes it more polar and less available to the stationary phase. 
 In Ion exchange chromatography, the stationary phase contains ionic groups like NR3+ or 
SO3- , which interact with the ionic groups of the sample molecules. This is suitable for the 
separation of charged molecules only. Changing the pH and salt concentration can modulate the 
retention. 
 
 
 
Ion pair chromatography  
 It may be used for the separation of ionic compounds and this method can also substitute for ion 
exchange chromatography. Strong acidic and basic compounds may be separated by reversed 
phase mode by forming ion pairs (columbic association species formed between two ions of 
opposite electrical charge) with suitable counter ions. This technique is referred to as reversed 
phase ion pair chromatography or soap chromatography. 
Affinity chromatography 
It uses highly specific biochemical interactions for separation. The stationary phase contains 
specific groups of molecules which can absorb the sample if certain steric and charge related 
conditions are satisfied. This technique can be used to isolate proteins, enzymes as well as 
antibodies from complex mixtures. 
Size exclusion chromatography  
 It separates molecules according to their molecular mass. Largest molecules are eluting first and 
the smallest molecules are eluting last. This method is generally used when a mixture contains 
compounds with a molecular mass difference of at least 10 %. This mode can be further sub 
divided into gel permeation chromatography (with organic solvents) and gel filtration 
chromatography (with aqueous solvents). 
 The various components of HPLC are pumps (solvent delivery system), mixing unit, gradient 
controller and solvent degasser, injector (manual or auto), guard column, analytical columns, 
detectors, recorders and/or integrators. Recent models are equipped with computers and software 
for data acquisition and processing. The choice of the column should be made after a careful 
consideration of the mode of the chromatographic technique. Three types of columns available 
based upon the type of packing and particle size, namely, rigid solids, hard gels and porous and 
pellicular layer beads. The columns of smaller particles (3-10uM) are always preferred because 
the offer high efficiency (number of theoretical plated/meter) and speed of analysis. 
The different types of detection used in HPLC methods based on ultraviolet (UV), fluorescence, 
refractive index, mass spectrophotometric and electrochemical. In most cases, method 
development in HPLC is carried out with UV detection using a variable wavelength 
spectrophotometric detector or a diode array detector (DAD). 
Digital electronic integrators are widely used today in HPLC for measuring peak areas. These 
devices automatically sense peaks and print out the areas in numerical form. Computing  
integrators are even more sophisticated and offer a number of features in addition to basic digital 
integration because these devices have both memory and computing capabilities to upgrade 
integrating parameters to maintain accuracy as the separation progress and eluting peaks become 
broader. Many of these devices print out a complete report, including names of the compounds, 
retention times, peak areas and area correction factors. With the help of peak area and height 
values, the peak width can be calculated (considering the peak as a triangle) and it can also be 
used for the calculation of number of theoretical plates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
   
 
 
 
 
 
 
 
                                    2.    DRUG PROFILE  
ADAPELENE 
Appearance  : smooth white powder 
Chemical Name : 6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid 
Molecular formula    : C28H28O3 
Molecular weight : 412.53 
Solubility: Insoluble in water 
                Soluble in Tetrahydrofuran 
                Sparingly soluble in Ethanol 
Adapalene is a topical retinoid primarily used in the treatment of acne and is also used to treat 
keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the 
trade names DIFFERIN in some countries, and ADAFERIN in India. 
Chemical Structure: 
 
 
                          
 
 
 
Pharmacology: 
Adapelene is a chemically stable retinoid like compound. Biochemical and pharmacological 
profile studies have demonstrated that adapelene is a modulator of cellular differentiation, 
keratinization and inflammatory processes all of which represent important features in the 
pathology of acne vulgaris. Adapelene has a retinoid structure and adamantine group is attached. 
Retinoic acid belongs to the group Vitamin A, and plays a role in non-vision functions – 
regulating the growth and differentiation of normal and malignant cells, whereas retinal 
(metabolically active aldehyde of retinol) is used in vision functions as a component of 
photoreceptor pigment in the retina of the eye. 
Pharmacological actions: 
Anti-acne 
Anti-retinoic 
Dermatologic 
Non-narcotic analgesic 
Non-steroidal Anti-inflammatory 
Peripheral Nervous System Agent 
Sensory System Agent 
Mechanism of Action: 
Mechanistically, Adapalene binds to specific retinoic acid nuclear receptors but does not bind to 
the cytosolic receptor protein. Although the exact mode of action of  Adapalene is unknown, it is 
suggested that tropical Adapalene may normalize the differentiation of follicular epithelial cells 
resulting in decreased microcomedone formation. 
The exact mechanism is not known. Adapalene exhibits some retinoic acid- like activity but it also 
has additional effects.it is thought that Adapalene reduces important features of the pathology of 
acne vulgaris by normalizing the differentiation of  follicular epithelial cells and  keratinization  to  
prevent microcomedone formation, similar to the mechanism of retinoic acid. Unlike retinoic acid, 
Adapalene selectively binds to some nuclear retinoic acid receptors (RARs)and does not bind to 
cellular receptors called cytosolic retinoic acid  binding proteins (CRABPs). 
It is hypothesized that by selectively binding to certain nuclear retinoic acid receptors and not 
others, Adapalene enhances keratinocyte differentiation without including epidermal hyperplasia 
and several irritation, such as is seen with retinoic acid. Also Adapalene may help reduce cell-
mediated inflammation, an effect demonstrated by in vitro studies. Adapalene decreases formation 
of comedowns and inflammatory and non –inflammatory acne lesions. 
One other proposed mechanism of action is that it binds to the specific retinoic acid nuclear 
receptors but does not binds to the cytosolic receptor protein, Adapalene works by making the skin 
pores free from being clogged by helping the skin renew itself as a fast rate .the mechanism is still 
believed to be the same as with other retinoid which is increased cell turnover or peeling of the 
skin. Adapalene is also claimed to effect the cellular differentiation, keratinization. 
Absorption 
Absorption of adapalene through human skin is low. Only trace amounts (<0.25ng/mL) of parent 
substance have been found in the plasma of acne patients following chronic topical application of 
adapalene in controlled clinical trials. 
Toxicity 
The acute oral toxicity of adapalene in mice and rats is greater than 10mL/Kg. Chronic ingestion 
of the drug may lead to the same side effects as those associated with excessive oral intake of 
Vitamin A 
Carcinogencity/ Tumorigenicity 
Adapalene was not found to be carcinogenic in mice administrated topical doses of 0.3, 0.9, and 
2.6 mg per kg of body weight(mg/kg) per day. Oral doses of 0.15,0.5,and 1.5 mg/kg given to rats 
increased the incidence of follicular cell adenomas and carcinomas of the thyroid in female rats, 
and benign and malignant pheochromocytomas in the adrenal medulla in male rats .Although  no 
photo carcinogencity studies were conducted with adapalene ,other topical retinoids have shown 
increased risk of tumorigenicity in animals when they were exposed to sunlight or ultraviolet 
irradiation in the laboratory under certain circumstances but not in all test systems. The 
significance of these animal studies to humans is not known. 
Pregnancy/reproduction 
Pregnancy 
Adequate and well controlled studies in humans have not been done. It is recommended that 
pregnant women not use adapalene, based on data for other topical retinoid. As a general 
precaution, women of reproductive age may want contraception counselling before initiating 
treatment. 
Teratologic studies of tropical adapalene use in rats and rabbits are in conclusive. An increased 
number of ribs were seen in studies done in rats given topical doses of 0.6,2 and 6 mg/kg a day 
(doses up to 150 times greater than usual tropical human dose) fetotoxicity was not seen in rats or 
rabbits at these doses. In oral doses of 25mg/kg a day, adapalene is teratogenic in rats, rabbits. 
 
Paediatrics 
No information is available on the relationship of age to the effects of adapalene in paediatric 
patients. Safety and efficacy in children up to 12 years of age have not been established. 
Adverse Effects 
The following side/adverse effects have been selected on the basis of their potential clinical 
significance (possible signs and symptoms in parentheses where appropriate)- not necessarily 
inclusive 
Erythema (redness of skin) 
Pruritus (itching of skin) 
Scaling (dryness and peeling of skin) 
 
 
 
 
  
 
                      
 
 
 
 
 
                                       4.   LITERATURE REVIEW 
 
1. 1.R.Ruhul, R.Thiel, T.S Lacker have reported about the synthesis. High performance liquid 
chromatography- nuclear magnetic characterization and pharmacokinetics in mice of 
CD271 glucereonide. (Adapalene). 
2. B Shroot, S Michael have reported about the pharmacology and chemistry of Adapalene. 
3. B Martin, D Montels and Watts have reported about the chemical stability of Adapalene 
and Tretionin when combined with benzoyl peroxide in presence and in absence of visible 
light and ultra violet radiation. Adapalene and tretinoin are molecules used in the topical 
treatment of acne vulgaris. Commercial formulations (adapalene 0.1% gel and tretinoin 
0.025% gel) were mixed with equal volumes of commercially available benzoyl peroxide 
formulation (10% lotion) and subsequently exposed to light over 24 h. With and without 
exposition to light, adapalene exhibits a remarkable stability whereas tretinoin is very 
sensitive to light and oxidation. The combination of benzoyl peroxide and light results in 
more than 50% degradation of tretinoin in about 2 h and 95% in 24 h. 
4. Ofgain C et al. Have reported about the stability testing of active ingredients through the 
principle of accelerated degradation. 
5. R Rahul, H Nau have reported about the determination of Adapalene and retinol in plasma 
and tissue by on-line solid-phase extraction and HPLC analysis. 
6. B Martin, C Meunier have reported about the chemical stability of Adapalene and 
Tretionin when combined with benzoyl peroxide in presence and in absence of light.  
7. Eric A Schimtt et al have reported about the rapid, practical and predicative excipient 
compatibility screening using iso- thermal microcalorimetry. 
8. D Rigopoulos, D Joannides, D Kalageromitros have reported about the comparison of 
topical retinoids in the treatment of acne. 
9. Drug bank provides general information, chemical structure, standards, indications, 
mechanism of action about the drug adaplene. 
10. British Journal of Dermatology provides ample lot information about the clinical aspects 
and adverse drug reactions caused by the drug Adapalene. 
11. Chandra, Pradeep have reported Design, development and formulation of antiacne 
dermatological gel Adapalene. 
 
 
 
 
  
 
 
     
              
 
 
 
 
 
                                                 OBJECTIVE 
The objective of the current project is to develop the study to indicate the stability of adapalene 
and also to assess the preservatives using a reverse-phase High Performance liquid 
Chromatographic method throughout its storage and also to determine the shelf-life, which is the 
storage time at a particular condition during which the pharmaceutical product will still cope up 
with its compendial specifications. Stability is an absolutely necessary factor of quality, safety and 
efficacy of a drug product. A pharmaceutical product, which is not of desirable stability, may lead 
to physical changes (hardness, change in release rate, phase separation, difference in expected 
consistency etc.) as well as chemical characteristics (formation of toxic decomposition by 
products). Similarly if a sterile preparation fails to meet its sterility criteria that too can be fatal. 
The purpose of carrying out the project work on stability studies is to fulfil the following 
objectives: 
 To study how to furnish a product and its packaging, so that the product has necessary 
aesthetics and consistency during the desired Shelf-life under the specified conditions of 
storage. 
 To develop and appropriate formulation of the drug Adapalene and thereafter to design a 
good and Adaptive container closure. 
 To provide the evidence on how the quality of a drug substance/drug product varies with 
time under the influence of a variety of environmental factor such as temperature, 
humidity and light and to establish a retest period/Shelf-life. 
 To carry out the stability studies of Adapalene using a well-defined pre-determined 
stability study tests/parameters like Description, Viscosity, Water, Related Substance and 
Assay. 
 
 
 
 
 
 
 
                                                              
 
 
 
 
 
 
 
 
                      
 
 
 
 
 
 
 
 
                                        5. METHODOLOGY 
METHOD OF ACCELERATED STABILITY STUDY OF ADAPALENE GEL 
BY HPLC IN PHARMACEUTICAL FORMULATIONS 
 
 ABSTRACT 
 
The  stability  studies of commercially available Adapalene gel (0.1%w/w& 0.3%w/w).in 3 
batches packed in the container closure system proposed for marketing were carried out for 6 
months by subjecting them to three different stability testing conditions which  are, 
             
 Accelerated Stability Testing (40ºC±2ºC/75%RH±5%RH) 
 Intermediate Stability Testing (30ºC±2ºC/65%RH±5%RH) 
 Long- Term Stability Testing (25ºC±2ºC/60%RH±5%RH) 
 
The samples were withdrawn at the respective time intervals as proposed by ICH guidelines and 
were analysed for appearance, Description, viscosity, pH, Water content, Related Substance, 
Assay, potency, and preservative content. 
 
The results of all the stability studies carried out at 0.3.and 6 months‟ time period at three different  
stability conditions were found to be well within the acceptance criteria and was concluded that 
Adapalene gel (0.1%w/w& 0.3%w/w).were found to be stable till sixth month study and further 
studies and the detailed further studies are carried. 
 
 
 
 
 
 
 
 
 
 
5. METHOD OF ACCELERATED STABILITY STUDY OF ADAPALENE 
GEL 
 
Table No: 11 
 
         Test    Specification Limits   Method 
Description 
 
 
Spread ability and 
Texture 
 
 
Identification by HPLC 
 
 
 
 
 
 
 
 
 
Viscosity 
 
PH 
 
Minimum Fill 
 
 
 
 
 
Water content by KF 
 
Assay by HPLC 
     Adapalene 
 
 
White, smooth, homogenous gel 
 
 
Smooth emollient gel 
 
 
 
In assay the Adapalene  peak in the 
chromatogram obtained with the sample 
solution should have the retention time 
as that of the peak due to Adapalene in 
the chromatogram obtained with the 
standard solution 
 
For information only 
 
 
 
Between  5 – 5.6 
 
 
The average net column of the 10 tubes 
should not be less than the labelled 
amount 
 
 
 
For information only 
 
Label claim                     Limits 
0.1%                  (0.090%- 0.110%) 
                   (90% - 110% of label claim) 
  IH 
 
 
  IH 
 
 
 
 
 
  IH 
 
 
 
 
 
 
 
 
 IH 
 
AD/01 
 
 
 USP<755> 
 
 
 
AD/01 
 
 
    IH 
 
 
 
 
 
 
 
 
 Test Specification Limits Method 
09) Related substances by 
HPLC. 
   a) Any unknown impurity 
 
   b) Total impurity 
 
10)Preservative content by 
HPLC 
 
 
Not more than 0.1% 
 
Not more than 2.0% 
 
Label claim                          Limits 
0.1% w/w                        0.08% - 0.12% 
                    
                     (80% - 120% of label claim) 
 
 
 
IH 
 
 
 
 
IH 
 
 
Reference: STP No: AD/FRSDP/TO3/R 
Storage: Store at controlled room temperature between 200c- 250c (680F -770F) with excess ions 
permitted between 590F and 860F (150c -300c).protect from freezing. 
Packing: In Laminated tubes 
 
Note: 1) Report the assay values in percentage and percentage of label claim 
         2) IH refers to in-house. 
 
Test procedures 
1) Description: 
Take out a sufficient quantity of sample from the tube from few tubes on a butter paper and record 
the apparent consistency, transparency, translucency and colour. 
Record and report the findings. 
 
2) Spreadability and Texture: 
Take out sufficient quantity for few tubes and spread on a butter paper and check the texture. 
Record and report the findings. 
 
 
3) Identification by HPLC: 
3.1) Check whether the RT (retention time) of Adapalene in the chromatogram of the sample is 
preparation and standard preparation are identical, as obtained in the test for Assay. 
3.2) Record and report the findings.  
4) Viscosity: 
4.1) instrument: Brookfield‟s Viscometer 
4.2) Instrument parameters: 
                           Spindle         : T bar spindle 
                           Reading time:  After 10 min 
4.3) Procedure: 
By using sufficient quantity of sample carry out the test as per the SOP of the Brookfield‟s 
Viscometer. 
4.4)  Record and report the findings. 
5) PH 
5.1) Take out a sufficient quantity of sample from the tube and dissolve in it in water. Dip the 
electrode into it and note the readings immediately. 
5.2) Record and report the findings. 
6) Minimum fill: 
6.1) Select a sample of 10 filled tubes. 
6.2) Remove any labelling that might be altered in weight during the removal of the tube contents. 
Thoroughly clean, rinse and dry the outside of the tube by any suitable means (preferably by a 
means of cotton). Then weigh the container individually. 
 
 
6.3) Dry and weigh each empty tubes 
6.5) The difference between 2 weights is the net weight of the contents of the tube. 
6.6) calculate the content per tube using the following expression. 
Net content per tube in gm = Gross Weight of the tube with the closure in g – Weight of the 
empty tube with their closure and other parts in g. 
6.7) Calculate the average net content/tube = sum of the net content of all tubes 
        10 
 7) Water content: 
 Determination of water: 
 The water content in the drug product has significant importance since it affects the physical 
characteristic, microbiological stability and shelf life of the product. 
As the water content directly influences the quality, process ability, shelf life and stability of a 
wide range of products, various physical and chemical methods are used to determine the water 
content. Among these, the Karl Fisher Titration has established itself as a reference method for 
general use. It is characterized by its high specificity and precision and works over a wide 
concentration range from ppm up to 100% .Additional advantages are short determination times. 
The trimetric determination of water is based up on the quantitative reaction of water with an un 
hydrous solution of sculptures dioxide and iodine in the presence of buffer that reacts with 
hydrogen ions. The reaction for the oxidation of the alkyl sulphite anion to alkyl sulphate by 
iodine is given below: 
CH3OH + SO² + RN → [RNH]SO3CH3 
H2O + I2 + [RNH]SO3CH3 + 2RN → [RNH]SO3CH3 +2 [RNH]I 
Apparatus: 
 Auto KARL FISHER titrator 
 
Reagent: iodosulphourous reagent .commercially available stabilized solution of Karl Fischer 
type reagent may be used. Standardize the reagent before use. 
Protect it from moisture while in use. 
Standardization of the reagent: 
Place about 20ml of anhydrous methanol in the titration vessel and titrate to the electrometric end 
point with the reagent. Add accurately weighed suitable amount of (25-40mg) water and titrate to 
the end point. Calculate the water –equivalent of reagent in mg/ml .the minimum water equivalent 
is 3.5 mg of water per ml of reagent. 
Calculate the water equivalent factor, in mg of water per ml of the reagent by the formula.  
                                       F = w/v 
Where, 
W= weight of water taken in mg 
V =volume of reagent required in ml 
Procedure: 
Add 20 ml of un hydrous methanol to the titration vessel and titrate to the amperometric end point 
with the Karl Fisher Reagent. Quickly add the accurately weighed sample (0.3g), mix for 1 min 
and again titrate with KARL Fischer reagent to the amperometric and point. 
Calculation:  
                    water (%w/w) (by KF) = V×F×100 
                                                            W 
       Where, V = volume in ml of KARL Fischer reagent consumed 
          F = water equivalence factor of the reagent (mg/ml) 
         W = weight of sample taken in mg. 
 
8) Assay by HPLC 
 Instrument: HPLC 
Instrument specifications 
The HPLC system consisted of an Agilent 1100 series HPLC quaternary pump (G1311A), Agilent 
1100 series Photodiode array detector (G1315A), with a 10mm path length cell, Agilent on –line 
solvent vacuum degasser (G1379A),and an Agilent auto sampler (G1313A). the data were 
acquired and processed by means of chemstation software version 3.02. Analytical Column: 
4.6mm×250mm i.e,5µmm  LI:Cosmosil C -18 or Equivalent. 
8.1) Chemical reagents 
 Acetonitrile  -  HPLC     grade  
 Tetrahydrofuran  - HPLC grade 
 Trifluroacetic acid  - AR grade 
 
8.2)  preparation of Mobile phase:  
Mix Acetonitrile, Tetrahydrofuran, Trifluroacetic acid and water in the ratio 430:360:210:0.2. 
Then subject to degas. 
8.3) Chromatographic Conditions 
 Column : Cosmosil C18,250×4.6mm, 5µm 
 Flow rate : 1ml/min 
 Run time : 15 min 
 Detector : Photodiode array detector 
 injection volume : 20µl 
 Wave length  : 235nm 
 8.4) Diluent:  
Use mobile phase as diluent. 
 
 8.5)  Preparation of Standard solution: 
  Weigh accurately about 20.0 mg of Adapalene standard into a 100 ml volumetric flask add 50 ml 
of Tetrahydrofuran. Sonic ate to dissolve Make up to the volume with Tetrahydrofuran. Further 
dilute 50 ml, of this solution to 500ml with the diluents and mix. 
8.6) Preparation of sample solution: 
 Gel (0.1%w/v): Weigh accurately about 2.0 g of Adapalene gel sample in to a 100ml, volumetric 
flask. Add 10.0ml of Tetrahydrofuran, sonic ate to dissolve .Make up to the volume with  the 
diluent and mix. Filter thoroughly through a 0.45 min Nylon filter paper. 
Gel (0.3%w/v): Weigh accurately about 6.7g.of Adapalene gel sample in to a 100ml, volumetric 
flask. Add 10.0ml of Tetrahydrofuran, sonic ate to dissolve .Make up to the volume with  the 
diluent and mix. Filter thoroughly through a 0.45 min Nylon filter paper. 
8.7) Procedure: 
1) Inject blank (diluents 1 injection), standard (5) injections. Then check for system suitability 
2) The RSD (relative standard deviation) for Adapalane area response from 5 injections of 
standard solution not be more than 20%. 
3) The tailing factor for the adapalene peak should not be more than 2.0. 
4) The theoretical plates for the Adapalene should not be less than 200. 
5) If the system suitability parameters passes the required criteria inject the sample solution (2 
injections) and record their response. 
8.8) Calculations: 
Calculate the content of the Adapalene in percentage by using the formula. 
 
Adapalene in % = AS   X   WS   X    DT   X   P     X   100 
                            AT         DS         WT         LC 
 
AS = Average area of Adapalene peak from the sample solution  
 
AT = Average area of Adapalene peak from the standard solution 
WT = weight of Adapalene sample in mg 
WS = weight of Adapalene standard in mg 
DS = Dilution of the standard solution 
DT = Dilution of the sample solution 
LC = label claim of adapalene in % w/w 
P =Potency of Adapalene standard in % w/w on as is basis 
 
Adapalene in percentage label claim = Content of Adapalene in % × Adapalene label claim in % 
                                                                                             100 
9) Related substance by HPLC 
9.1) Instrument: HPLC 
9.2) preparation of Mobile phase:  
Mix Acetonitrile, Tetrahydrofuran Water and ,Trifluroacetic acid  in the ratio 430:360:210:0.2. 
Then subject to degas. 
9.3) Chromatographic Conditions 
 Column : Cosmosil C18,250×4.6mm, 5µm 
 Flow rate : 1ml/min 
 Detector : Photodiode array detector 
 injection volume : 20µl 
 Wave length  : 235nm 
 Run time : Standard   : 15 min 
                                                             : Blank     : 30 min 
                                                             : Diluent   : 30 min 
 
9.4) Diluent:  
Use mobile phase as diluent. 
9.5) Preparation of Blank: 
Pipette out 5.0 ml of Tetrahydrofuran .in to a 50 ml volumetric flask. Dilute to the volume with 
the diluent and mix. 
9.6) Preparation of Standard solution:  
1) Weigh accurately about 10.0 mg of Adapalene standard into a 100 ml volumetric flask .Add 50 
ml of Tetrahydrofuran. and Sonic ate to dissolve Make up to the volume with Tetrahydrofuran. 
2) Pipette out 5ML of the above solution in to a %)ml volumetric flask, dilute to the volume with 
tetrahydrofuran and mix well. 
3) Further dilute 0.5 ML of the above solution to 50ML with the diluent and sonicate to dissolve. 
9.7) Preparation of sample solution: 
 Gel (0.1%w/v): Weigh accurately about 2.0 g of Adapalene gel sample in to a 50 ml, 
volumetric flask. Add 2.5 ml of Tetrahydrofuran,and mix well. Then add about 7.5 ml of diluent 
and mix well. Then sonic ate the above solution until the contents dissolve completely.  
2)  Transfer the above solution in to a 25ML volumetric flask and rinse it twice with 5 ml of the 
diluent. Transfer the total volume in to the previous 25ml volumetric flask. Make up to the 
volume with the diluents and mix well 
3) Filter thoroughly through a 0.45 min Nylon filter paper. 
Gel (0.3%w/v): Weigh accurately about 2.5g.of Adapalene gel sample in to a 50ml, volumetric 
flask. Add 2.5ml of Tetrahydrofuran, sonic ate to dissolve .Then add about 7.5 ml of diluents and 
mix well. Sonicate to dissolve the sample completely. 
2) Transfer the solution into a 25 ml volumetric flask and rinse twice with 5 ml of diluents. 
Transfer the total volume into the previous 25 ml volumetric flask. Make up to the volume with 
the diluent and mix. 
3) Filter thoroughly through a 0.45 min Nylon filter paper. 
 
 
 10) Preservative content by HPLC: 
10.1) Instrument: HPLC 
10.2) Mobile phase: Mix Acetonitrile, Tetrahydrofuran Water and, Trifluroacetic acid in the 
ratio 430:360:210:0.2%v/v  and mix well. 
 
10.3) Chromatographic Conditions 
 Column : Cosmosil C18,250×4.6mm, 5µm 
           Flow rate : 1ml/min 
 Detector : Photodiode array detector 
 injection volume : 20µl 
 Wave length  : 235nm 
 Run time : Standard  : 15 min 
                                                             Blank     : 30 min 
                                                             Diluent  : 30 min 
10.4) Diluent:  
Use mobile phase as diluent. 
10.5) Preparation of Blank:  
Pipette out 5.0 ml of Tetrahydrofuran into a 50 ml volumetric flask. and mix well. Dilute to the 
volume with the diluent and mix. 
10.6) Preparation of Standard solution:  
1) Weigh accurately about 10.0 mg of Adapalene standard into a 100 ml volumetric flask .Add 50 
ml  of Tetrahydrofuran. and Sonic ate to dissolve Make up to the volume with Tetrahydrofuran. 
2) Pipette out 5ML of the above solution  in to a %)ml volumetric flask, dilute to the volume with 
tetrahydrofuran and mix well. 
 3) Further dilute 0.5 ML of the above solution to 50ML with the diluents and mix well. 
 
10.7) Preparation of sample solution: 
 Gel (0.1%w/v): 
1) Weigh accurately about 2.5 g of Adapalene gel sample in to a 50 ml, volumetric flask. Add 2.5 
ml of Tetrahydrofuran,and mix well. Then add about 7.5 ml of diluent and mix well. Then sonic 
ate the above solution until the contents dissolve completely.  
2)  Transfer the above solution in to a 25ML volumetric flask and rinse it twice with 5 ml of the 
diluent. Transfer the total volume in to the previous 25ml volumetric flask. Make up to the 
volume with the diluents and mix well 
3)Filter thoroughly through a 0.45 min Nylon filter paper. 
Gel (0.3%w/v): 
1) Weigh accurately about 2.5g.of Adapalene gel sample in to a 50ml, volumetric flask. Add 
2.5ml of Tetrahydrofuran, sonic ate to dissolve .Then add about 7.5 ml of diluents and mix well. 
Sonic ate to dissolve the sample completely. 
2) Transfer the solution into a 25 ml volumetric flask and rinse twice with 5 ml of diluents. 
Transfer the total volume into the previous 25 ml volumetric flask. Make up to the volume with 
the diluent and mix. 
3) Filter thoroughly through a 0.45 min Nylon filter paper. 
Number of batches performed 
In this project the no: of batches performed are as follows 
Gel (0.3%w/v) – 2 Batches 
Gel (0.1%w/v) – 3 Batches 
 
 
 
  
 
 
                                         5.1 RESULTS 
The different batches of Adapalene were subjected to the study as per the protocol. The 
chromatogram obtained and the results are given below. 
 
 
Fig 1 – Chromatogram of initial assay - standard 
 
 
 
Fig 2 - Chromatogram of initial assay – sample 
 
 
  
 
 
Fig 3 - Chromatogram of initial - related substance - standard 
 
 
 
Fig 4 - Chromatogram of initial - related substance - sample 
 
 
 
  
 
Fig 5 - Chromatogram of initial – preservative content – standard 
 
 
Fig 6 - Chromatogram of initial – preservative content - sample 
 
 
 
 
  
Fig 7 – Chromatogram of Second month – assay 
 
 
 
 
Fig 8 - Chromatogram of Second month – related substance (40 ºC + 75% RH) 
 
 
 
 
 Fig 9 – Chromatogram of Second month – preservative content (40 ºC / 75% RH) 
 
 
 
Fig 10 - Chromatogram of Third month – assay – (25 ºC / 60% RH) 
 
 
 
 
 
 
 Fig 11 - Chromatogram of Third month – related substance (25 ºC / 60 RH) 
 
 
 
Fig 12 - Chromatogram of  Third month – preservative content (25 ºC / 60 RH 
 
 
 
 
 Fig 13 - Chromatogram of Third month – assay – (30 ºC / 65% RH) 
                           
 
  
 
Fig 14 - Chromatogram of Third month – related substance (30 ºC / 65% RH) 
 
 
 
        
 
 Fig 15 – Chromatogram  of Third month – preservative content (30 ºC / 65 RH) 
   
 
 
                                                                                                                                                   
Fig 16 - Chromatogram of Third month – assay – (40 ºC / 75% RH) 
 
 
 
 
  
Fig 17 – Chromatogram of Third month – related substance - (40 ºC / 75% RH) 
 
 
 
 
Fig 18 – Chromatogram of Third month – preservative content - (40 ºC / 75% RH) 
 
 
 
 
 
 
  
Fig 19 – Chromatogram of Sixth Month – Assay (25 ºC / 60% RH) 
 
 
 
Fig 20 – Chromatogram of Sixth Month – Related substance (25 ºC / 60 RH) 
 
 
 
 
 
 Fig 21 – Chromatogram of Sixth Month – Preservative content (25 ºC / 60 RH) 
 
 
 
 
 
Fig 22 – Chromatogram of Sixth Month – Assay - (30 ºC / 65% RH) 
 
 
 
 
 
 Fig 23 – Chromatogram of Sixth Month – Related substance - (30 ºC / 65% RH) 
 
 
 
Fig 24 – Chromatogram of Sixth Month – Preservative content - (30 ºC / 65% RH) 
 
 
 
 
  
Fig 25 – Chromatogram of Sixth Month – Assay - (40 ºC / 75% RH) 
 
 
 
Fig 26 – Chromatogram of Sixth Month – Preservative content - (40 ºC / 75% RH) 
 
 
 
 
 Fig 27 – Chromatogram of Sixth Month – Related substance - (40 ºC / 75% RH) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No: 12; Batch No: A (Gel – 0.3% w/w) Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances 
(by HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Tota
l 
Imp 
NM
T 
2.0
% 
Initial 
White smooth 
homogenous 
gel Complies 5.22 93.01% 0.01% 
0.03
% 104.10% 100.90% 4210 
1 M 
White smooth 
homogenous 
gel Complies 5.40 90.00% 0.01% 
0.03
% 103.20% 96.80% 7520 
2 M 
White smooth 
homogenous 
gel Complies 4.89 93.29% ND ND 102.10% 95.00% 7780 
3 M 
White smooth 
homogenous 
gel Complies 5.20 91.41% ND ND 105.10% 97.70% 6200 
6 M 
White smooth 
homogenous 
gel Complies 5.17 88.88% ND ND 105.70% 98.20% 7300 
 
Table No: 13; Condition: 30 ºC ± 2 ºC / 65% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.22 93.01% 0.01% 0.03% 104.1% 100.90% 4210 
1 M 
White smooth 
homogenous 
gel Complies 5.40 90.00% 0.01% 0.03% 103.2% 96.80% 7520 
2 M 
White smooth 
homogenous 
gel Complies 4.89 93.29% ND ND 102.1% 95.00% 7780 
3 M 
White smooth 
homogenous 
gel Complies 5.13 83.66% ND ND 99.1% 96.70% 6600 
6 M 
White smooth 
homogenous 
gel Complies 5.21 91.92% ND ND 103.2% 95.70% 7400 
 
Table No: 14; Condition: 40 ºC ± 2 ºC / 75% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances 
(by HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Tota
l 
Imp 
NM
T 
2.0
% 
Initial 
White smooth 
homogenous 
gel Complies 5.22 93.01% 0.01% 
0.03
% 104.10% 100.90% 4210 
1 M 
White smooth 
homogenous 
gel Complies 5.40 90.00% 0.01% 
0.03
% 103.20% 96.80% 7520 
2 M 
White smooth 
homogenous 
gel Complies 4.89 93.29% ND ND 102.10% 95.00% 7780 
3 M 
White smooth 
homogenous 
gel Complies 5.25 94.87% ND ND 102.90% 95.10% 7140 
6 M 
White smooth 
homogenous 
gel Complies 5.23 87.93% ND ND 104.10% 95.40% 7150 
 
Table No: 15; Batch No: B (Gel – 0.3% w/w) Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances 
(by HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Tota
l 
Imp 
NM
T 
2.0
% 
Initial 
White smooth 
homogenous 
gel Complies 5.21 93.04% 0.01% 
0.03
% 103.10% 100.90% 4210 
1 M 
White smooth 
homogenous 
gel Complies 5.42 90.8% 0.01% 
0.03
% 104.20% 96.80% 7520 
2 M 
White smooth 
homogenous 
gel Complies 4.87 93.48% ND ND 101.91% 95.00% 7780 
3 M 
White smooth 
homogenous 
gel Complies 5.17 91.39% ND ND 106.10% 97.70% 6200 
6 M 
White smooth 
homogenous 
gel Complies 5.19 88.76% ND ND 104.90% 98.20% 7300 
 
Table No: 16; Condition: 30 ºC ± 2 ºC / 65% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.24 93.03% 0.01% 0.03% 104.3% 101.1% 4230 
1 M 
White smooth 
homogenous 
gel Complies 5.42 90.02% 0.01% 0.03% 103.4% 97.0% 7540 
2 M 
White smooth 
homogenous 
gel Complies 4.91 93.31% ND ND 102.3% 95.2% 7800 
3 M 
White smooth 
homogenous 
gel Complies 5.15 83.68% ND ND 99.3% 96.9% 6800 
6 M 
White smooth 
homogenous 
gel Complies 5.23 91.94% ND ND 103.4% 95.9% 7600 
 
 
Table No: 17; Condition: 40 ºC ± 2 ºC / 75% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.28 93.07% 0.01% 0.03% 104.7% 101.5% 4310 
1 M 
White smooth 
homogenous 
gel Complies 5.46 90.06% 0.01% 0.03% 103.8% 97.4% 7580 
2 M 
White smooth 
homogenous 
gel Complies 4.95 93.35% ND ND 102.7% 95.6% 7800 
3 M 
White smooth 
homogenous 
gel Complies 5.31 94.93% ND ND 103.5% 95.7% 7200 
6 M 
White smooth 
homogenous 
gel Complies 5.29 87.99% ND ND 104.7% 96.0% 7210 
 
 
Table No: 18; Batch No: C (Gel – 0.1% w/w) Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.62 NP ND ND 94.0% 109.1% 4490 
3 M 
White smooth 
homogenous 
gel Complies 5.63 95.73% 0.06% 0.03% 107.1% 106.7% NP 
6 M 
White smooth 
homogenous 
gel Complies 5.55 91.94% ND ND 110.2% 108.9% NP 
 
 
Table No: 19; Condition: 30 ºC ± 2 ºC / 65% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.62 NP ND ND 94.0% 109.1% 4490 
6 M 
White smooth 
homogenous 
gel Complies 5.59 95.39% 0.02% 0.02% 109.4% 103.2% 3950 
 
 
 
 
 
 
 
 
 
Table No: 20; Condition: 40 ºC ± 2 ºC / 75% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.62 NP ND ND 94.0% 109.1% 4490 
1 M 
White smooth 
homogenous 
gel Complies 5.45 96.87% ND ND 98.7% 103.7% 4140 
2 M 
White smooth 
homogenous 
gel Complies 5.32 99.54% 0.01% 0.03% 104.0% 106.5% 4270 
3 M 
White smooth 
homogenous 
gel Complies 5.59 94.40% 0.02% 0.03% 104.4% 105.4% 4370 
6 M 
White smooth 
homogenous 
gel Complies 5.60 85.92% ND ND 112.2% 107.3% NP 
 
Table No: 21; Batch No: D (Gel – 0.1% w/w) Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.34 93.22% ND ND 98.0% 99.2% 3600 
1 M 
White smooth 
homogenous 
gel Complies 5.52 89.64% 0.02% 0.02% 102.5% 96.6% 3830 
2 M 
White smooth 
homogenous 
gel Complies 5.32 90.47% ND ND 101.9% 99.32% 3770 
3 M 
White smooth 
homogenous 
gel Complies 5.49 89.70% ND ND 102.3% 94.19% 3330 
6 M 
White smooth 
homogenous 
gel Complies 5.05 88.34% ND ND 99.2% 92.6% 3800 
 
 
 
Table No: 22; Condition: 30 ºC ± 2 ºC / 65% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Parabe
n 
80.0% 
to 
110.0% 
Viscosi
ty cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.34 93.22% ND ND 98.0% 99.2% 3600 
1 M 
White smooth 
homogenous 
gel Complies 5.52 89.64% 0.02% 0.02% 102.5% 96.6% 3830 
2 M 
White smooth 
homogenous 
gel Complies 5.32 90.47% ND ND 101.9% 99.32% 3770 
3 M 
White smooth 
homogenous 
gel Complies 5.49 89.70% ND ND 102.3% 94.19% 3330 
6 M 
White smooth 
homogenous 
gel Complies 5.05 88.34% ND ND 99.2% 92.6%  3800 
 
 
Table No: 23; Condition: 40 ºC ± 2 ºC / 75% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapel
ene 
90.0% 
to 
110.0
% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maxim
um 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.34 93.22% ND ND 98.0% 99.2% 3600 
1 M 
White smooth 
homogenous 
gel Complies 5.52 89.64% 0.02% 0.02% 102.5% 96.6% 3830 
2 M 
White smooth 
homogenous 
gel Complies 5.32 90.47% ND ND 101.9% 99.32% 3770 
3 M 
White smooth 
homogenous 
gel Complies 5.49 89.70% ND ND 102.3% 94.19% 3330 
6 M 
White smooth 
homogenous 
gel Complies 5.05 88.34% ND ND 99.2% 92.6% 3800 
 
 
Table No: 24; Batch No: E (Gel – 0.1% w/w) Condition: 25 ºC ± 2 ºC / 60% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances 
(by HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Indivi
dual 
maxi
mum 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.15 95.93% ND ND 106.9% 113.2% 4280 
3 M 
White smooth 
homogenous 
gel Complies 5.07 92.61% ND ND 101.5% 109.6% 4190 
6 M 
White smooth 
homogenous 
gel Complies 5.29 93.67% ND ND 96.6% 98.5% 4800 
 
Table No: 25; Condition: 30 ºC ± 2 ºC / 65% ± 5% RH 
Period 
Descriptio
n 
Identificati
on by 
HPLC 
must 
comply pH 
Water 
content 
Related 
substances (by 
HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Parabe
n 
80.0% 
to 
110.0% 
Visco
sity 
cp 
Individ
ual 
maximu
m Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.66 NP ND ND 106.9% 109.7% 4590 
6 M 
White smooth 
homogenous 
gel Complies 5.63 95.99% 0.06% 0.06% 109.8% 103.6% 3850 
 
 
 
 
 
 
 
 
Table No: 26; Condition: 40 ºC ± 2 ºC / 75% ± 5% RH 
Period 
Descriptio
n 
Identification 
by HPLC 
must 
comply pH 
Water 
content 
Related 
substances 
(by HPLC) 
Assay 
Adapele
ne 
90.0% 
to 
110.0% 
Assay 
Methyl 
Paraben 
80.0% to 
110.0% 
Visco
sity 
cp 
Indivi
dual 
maxi
mum 
Imp 
NMT 
0.1% 
Total 
Imp 
NMT 
2.0% 
Initial 
White smooth 
homogenous 
gel Complies 5.15 95.95% ND ND 106.9% 113.2% 4280 
1 M 
White smooth 
homogenous 
gel Complies 5.36 87.15% ND ND 109.2% 100.2% 4030 
2 M 
White smooth 
homogenous 
gel Complies 5.48 94.88% ND ND 109.1% 108.5% 4160 
3 M 
White smooth 
homogenous 
gel Complies 5.03 90.22% ND ND 111.9% 111.6% 4260 
6 M 
White smooth 
homogenous 
gel Complies 5.31 93.22% ND ND 107.1% 94.3% 3970 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  
                                                   5.2. DISCUSSION 
 
This current dissertation named “METHOD OF ACCELERATED STABILITY STUDY OF 
ADAPALENE GEL BY HPLC IN PHARMACEUTICAL FORMULATIONS” were 
performed using 2 batches of 0.3%w/w and 3 batches of 0.1%w/w both packed in laminated tube 
containing 20g. Adapalene were subjected to accelerated   (40ºC ± 2ºC/75%RH ± 5%RH) 
Intermediate (30ºC ± 2ºC/65%RH ± 5%RH) and Long- Term  (25ºC ± 2ºC/60%RH ± 5%RH) 
stability storage conditions in stability chamber and various test parameters were analysed. 
 
The results obtained are discussed below: 
Description: A white smooth homogeneous gel packed in laminated tubes. 
At particular time instants the aesthetics as well as the chemical properties were checked and was 
found complied with the specification during the 6
th
 month study. 
 
Viscosity: The Adapalene gel formation was constantly assessed for its viscosity and it was 
found to meet the compendial requirements. 
 
pH: The pH of the reconstituted solution was measured using pH meter for all the batches of  
Adapalene and was found to be between (5-6) under Accelerated stability storage condition,(5.86- 
6.18) for intermediated stability storage condition and (5.96-6.14) for Long- term stability storage 
condition which well within the limits specified (Limit is between (5-7)). 
 
Related substances: The Related substance test were carried out using Reverse Phase HPLC 
with DAD detection and the concentration of related substance was found to be within limit. Total 
impurities were not more than 2.0%. At any instant during Accelerated stability storage condition, 
intermediated stability storage condition and  Long- term stability storage condition, the impurities 
were well within the limit. (Limit is NMT 0.2%). 
 
Water: The amount of water present in the samples were determined by titration with Karl 
Fischer reagent using Auto Karl Fischer titrator for all the batches of Adapalene gel at all-time 
points during Accelerated stability storage condition, intermediated stability storage condition and 
Long- term stability storage condition, it was found to be between 90%- 97% which was well 
meeting the specified limits.. 
Assay:  The percentage purity of Adapalene was carried out using RP-HPLC with DAD 
detection for all the batches at three stability storage conditions. The percentage purity of 
Adapalene was found to be (100%-110%) Under Accelerated stability storage condition,(96%- 
105%) under intermediated stability storage condition  (95%-100%) under Long- term stability 
storage condition. It was found that during all the time points, the % purity was well within the 
limits specified (Limit is 90.0% to 110%). 
 
The different stability test parameters like Description, Viscosity, pH, Related substances, 
Water and Assay were determined. 
 
The results or the values obtained all the time points were well acceptable within in the compendia 
requirements and hence it was found to comply within the specified limits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                                                              5.3. SUMMARY 
 
 
Adapalene gel (0.1%w/w&0.3%w/w) packed in final container (Essel pro –pack) were kept at 
Accelerated , intermediated and  Long- term stability storage condition in stability chamber and 
samples were drawn at regular intervals based on physical, chemical, biological tests, the analysis 
reports shows that the product is stable till 6 th month Accelerated stability storage condition. Also 
the viscosity and consistency studies show that the product is stable. The results is obtained are 
summarized below. The developed method was validated according to ICH guidelines and all the 
parameters were within the limits. 
 
Summarized data for Adapalene Gel (0.1%w/w&0.3%w/w) 
 
PRODUCT IDENTIFICATION 
BY HPLC MUST 
COMPLY 
PH WATER 
CONTENT 
RELATED 
SUBSTANCES 
(BY HPLC) 
ASSAY 
ADAPELENE 
90.0% TO 
110.0% 
ASSAY 
METHYL 
PARABEN 
80.0% TO 
110.0% 
VISCOSITY 
CP 
 
 
Adapalene 
Accelerated 5.51 96.85 complies 103.17 105.7 4210 
Intermediate 5.60 95.39 complies 108.90 106.2 4250 
Long term 5.59 94.50 complies 101.6 107.7 4490 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
6. CONCLUSION 
 
The  stability studies carried out by various stability indicating  parameters like Description, 
identification by HPLC,, pH, Related substances, Water,  Assay and preservative content for 
Adapalenegel(0.1%w/w&0.3%w/w)a3stabilityconditions..Accelerated stability conditions 
(40ºC±2ºC/75%RH±5%RH) Intermediate stability condition (30ºC±2ºC/65%RH±5%RH) and 
Long- Term stability condition (25ºC±2ºC/60%RH±5%RH) and compatibility studies. 
 
The development method was validated according to ICH guideness and all the parameters were 
within the limits. 
 
All the above tests indicated that the values obtained were well within the limits specified. No 
changes need to be introduced in formulation manufacturing process and proposed container and 
closure. 
 
Since the study was carried out for 6 months, further study need to be carried out for 9,12,18,24 
and 36 months as per the product specification under labelled storage conditions. 
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